Implications of CEA and p53 overexpression in the poor prognosis of colorectal cancer

Medical Oncology

Volumn 23, Issue 2, 2006, Pages 237-244

  Nasif, Wesam A ^a   Lotfy, Mahmoud ^a   El Sayed, Ibrahim H ^a   El Kenawy, Ayman El Meghawry ^a   El Shahat, Mohamed ^a   El Hak, Nabil Gad ^b  

^a MENOUFIA UNIVERSITY   (Egypt)

^b MANSOURA UNIVERSITY   (Egypt)

Author keywords

CEA; Colorectal cancer; p53

Indexed keywords

DNA; MONOCLONAL ANTIBODY; PROTEIN P53; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LOG RANK TEST; MALE; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; SAMPLE; SURVIVAL TIME;

ADULT; AGED; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DNA, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEX FACTORS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33646875057     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:2:237     Document Type: Article

References (45)

1. American Cancer Society. Cancer facts and figures. Available at: http://www.cancer.org/downloads/STT/CAFF_ finalPWSecured.pdf. Accessed August 4, 2004.
2. Hollstein M, et al. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 1994; 22: 3551-3555.
3. Prives C, Hall PA: The p53 pathway (review). J Pathol 1999; 187: 112-126.
4. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323-331.
5. Maki CG, Howley PM. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol 1997; 17: 355-363.
6. Maltzman W, Czyzyk L UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol 1984; 4: 1689-1694.
7. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993; 8: 307-318.
8. Kastan MB, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587-597.
9. el-Deiry WS, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
10. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1cyclin-dependent kinases. Cell 1993; 75: 805-816.
11. Han J, Sabbatini P, Perez D, Rao L, Modha D, White E. The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes Dev 1996; 10: 461-477.
12. Gold P, Freedman SO. Demonstration of tumor specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965; 121: 439-462.
13. Paxton RJ, Mooser G, Pande H, Lee TD, Shively JE. Sequence analysis of carcinoembryonic antigen: identification of glycosylation sites and homology with the immunoglobulin super-gene family. Proc Natl Acad Sci USA 1987; 84: 920-924.
14. Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989; 57: 327-334.
15. Kornek GV, Depisch D, Rosen HR, Temsch EM, Scheithauer W. Comparative analysis of CA72-4, CA195 and carcinoembryonic antigen in patients with gastrointestinal malignancies. J Cancer Res Clin Oncol 1992; 118: 318-320.
16. Posner MR, Mayer RJ. The use of serologic tumor markers in gastrointestinal malignancies. Hematol Oncol Clin North Am 1994; 8: 533-553.
17. Zhao JZ, Wu BH. Clinical significance of CA19-9 in diagnosis of digestive tract tumors. China Natl J New Gastroenterol 1997; 3: 253-254.
18. Kouri M, Pyrhnen S, Kuusela P. Elevated CA19-9 as the most significant prognostic factor in advanced colorectal carcinoma. J Surg Oncol 1992; 49: 78-85.
19. Zhao XY, et al. A clinical evaluation of serological diagnosis for pancreatic cancer. World J Gastroenterol 1998; 4: 147-149.
20. Marrelli D, et al. Prognostic significance of CEA, CA19-9 and CA72-4 preoperative serum levels in gastric carcinoma. Oncology 1999; 57: 55-62.
21. Ohuchi N, et al. Comparison of serum assays for TAG-72, CA19-9, and CEA in gastrointestinal carcinoma patients. Jpn J Clin Oncol 1989; 19: 242-248.
22. Fucini C, et al. Follow-up of colorectal cancer resected for cure. An experience with CEA, TPA, Ca19-9 analysis and second look surgery. Dis Colon Rectum 1987; 30: 273-277.
23. Guadagni F, et al. CA72-4 serum marker-a new tool in the management of carcinoma patients. Cancer Invest 1995; 13: 227-238.
24. Hedley DW. Flow cytometry using paraffin-embedded tissue: five years on. Cytometry 1989; 10: 229-241.
25. Zhang YL, Zhang ZS, Wu BP, Zhou DY. Early diagnosis for colorectal cancer in China. World J Gastroenterol 2002; 8: 21-25.
26. Li S, et al. Colorectal cancer screening for the natural population of Beijing with sequential fecal occult blood test: A multicenter study. Chin Med J 2003; 116: 200-202.
27. Thiis-Evensen E, Hoff GS, Sauar J, Majak BM, Vatn MH. Flexible sigmoidoscopy or colonoscopy as a screening modality for colorectal adenomas in older age groups? Findings in a cohort of the normal population aged 63-72 years. Gut 1999; 45: 834-839.
28. Repetto L, et al. Geriatric oncology: a clinical approach to the older patient with cancer. Eur J Cancer 2003; 39: 870-880.
29. Gatta G, Faivre J, Capocaccia R, Ponz de Leon M. Survival of colorectal cancer patients in Europe during the period 1978-1989. Eur J Cancer 1998; 34: 2176-2183.
30. Fletcher RH. Carcinoembryonic antigen. Ann Intern Med 1996; 104: 66-73.
31. Ballesta AM, Molina R, Filella X, Jo J, Gimenez N. Carcinoembryonic antigen in staging and follow-up of patients with solid tumors. Tumour Biol 1995; 16: 32-41.
32. Gebauer G, Müller-Ruchholtz W. CEA concentration in colon mucosa correlates with prognosis in colorectal cancer patients. Cancer Detection and Prevention 1998; 22(Sup1).
33. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996, by the American Society of Clinical Oncology. J Clin Oncol 1996; 14: 2843-2877.
34. Bast RC Jr., et al. Update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865-1878.
35. Bruinvels DJ, Stiggelbout AM, Kievit J, van Houwelingen HC, Habbema JD, van de Velde CJ. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 1994; 219: 174-182.
36. Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Physician 2003; 68: 1075-1082.
37. Nan K-J, Qin H-X, Yang G. Prognostic factors in 165 elderly colorectal cancer patients. World J Gastroenterol 2003; 9(10): 2207-2210.
38. Wang JP, et al. Multivariate regression analysis of clinicopathological characteristics and prognosis of colorectal cancer. Zhonghua Zhongliu Zazhi 2003; 25: 59-61.
39. Walker J, Quirke P. Prognosis and response to therapy in colorectal cancer. Eur J Cancer 2002; 38: 880-886.
40. Gu J, Ma ZL, Li Y, Li M, Xu GW. Angiography for diagnosis and treatment of colorectal cancer. World J Gastroenterol 2003; 9: 288-290.
41. Kanthan R, Radhi JM, Kanthan SC. Gallbladder carcinomas: an immunoprognostic evaluation of P53, Bcl-2, CEA and alpha-fetoprotein. Canad J Gastroenterol 2000; 14(3): 181-184.
42. Kim DY, Kim HR, Shim JH, Park CS, Kim SK, Kim YJ. Significance of serum and tissue carcinoembryonic antigen for the prognosis of gastric carcinoma patients J Surg Oncol 2000; 74: 185-192.
43. Zeng ZS, et al. p53 nuclear overexpression: an independent predictor of survival in lymph node - positive colorectal cancer patients. J Clin Oncol 1994; 12:2043-2050.
44. Tortola S, et al. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 1999; 17(5):1375-1381.
45. Shiota G, et al. Circulating p53 antibody in patients with colorectal cancer. Dig Dis Sci 2000; 45(1):122-128.